Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06027905 · ClinicalTrials.gov registry record · NA

Novartis - Closing the Gap in Cardiovascular Risk: Engage, Empower, Evaluate

A NA study of Hypertension, sponsored by Rush University Medical Center.

Completed
Registry status
NA
Development phase
445
Enrollment target
1
Study location

NCT06027905: Completed NA study of Hypertension, sponsored by Rush University Medical Center.

NCT06027905 is a NA study of Hypertension that has completed, run by Rush University Medical Center. The registered enrollment target is 445 participants, below the 3,506-participant average among 470 other Hypertension trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06027905, a NA study of Hypertension, has completed, sponsored by Rush University Medical Center.

COMPLETED
Registry status
NA
Development phase
445 participants
Enrollment target
1
Study location

Study Summary

This study aims to decrease the racial gap in high blood pressure in African American and Latinx patients in Rush University Medical Center clinics.

Primary Outcome

Percentage of total participants with improvement from stage II hypertension (140/90 mmHg or above) to blood pressure below 130/80 mmHg with home cuff through self monitoring

Conditions Studied

Interventions

  • OTHER E3 Remote Monitoring and Social Intervention

Study Locations (1)

Illinois

  • Rush University Medical Center - Chicago

Trial Details

FieldValue
Enrollment Target 445 participants
Start Date 2023-09-13
Est. Completion 2025-05-12
Phase NA
Rush University Medical Center

320 total trials

What the finished NCT06027905 record still lists

NCT06027905 is an interventional study that assigns participants to a tested intervention. The registered 445 participants enrollment target is mid-sized for trials with a published cap, below the 3,506-participant average among 470 other Hypertension trials with a reported enrollment target (87% lower).

The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 1 intervention - of which E3 Remote Monitoring and Social Intervention is the first listed.

NCT06027905 reports a single indexed study location in Illinois.

Frequently Asked Questions

What is clinical trial NCT06027905 about?

NCT06027905 is a clinical study titled "Novartis - Closing the Gap in Cardiovascular Risk: Engage, Empower, Evaluate". This study aims to decrease the racial gap in high blood pressure in African American and Latinx patients in Rush University Medical Center clinics.

What is the current status of trial NCT06027905?

This trial is currently completed. It is a NA study. The enrollment target is 445 participants. The study started on 2023-09-13. Estimated completion is 2025-05-12.

What conditions does trial NCT06027905 study?

This clinical trial studies the following conditions: Hypertension.

What interventions are being tested in trial NCT06027905?

The interventions under investigation include: E3 Remote Monitoring and Social Intervention (OTHER).

Who is sponsoring clinical trial NCT06027905?

This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06027905 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06027905's enrollment target sits among peer trials

445 137th of 470 higher than 333 of 470 other Hypertension trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01280994 · 445 participants · Phase 2

    Hyperpolarized 129Xe MRI for Imaging Pulmonary Function

  • NCT03504800 · 445 participants

    OCT in Diagnosis of Irregular Corneas

  • NCT04751435 · 445 participants · NA

    Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients

  • NCT06348394 · 444 participants · NA

    Intracardiac Versus Transesophageal Echocardiographic Guidance for Left Atrial Appendage Occlusion

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06027905, the US trial registry maintained by the National Library of Medicine. NCT06027905 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.